隶属于 china grand enterprises, inc.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1993
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Heidelberg Pharma AG and Huadong Medicine received China NMPA Clinical Trial Approval for a Phase Ib/II study of pamlectabart tismanitin (HDP-101) in relapsed/refractory multiple myeloma. - The trial will evaluate HDP-101 in combination with either pomalidomide and dexamethasone or daratumumab and dexamethasone in patients with at least one prior line of therapy. - HDP-101 is a BCMA-targeting ADC using Amanitin-based ATAC technology and has received FDA Orphan Drug and Fast Track Designations. - Huadong Medicine will conduct the trial in China and bear development costs under a 2022 partnership granting exclusive rights across 20 Asian markets.
- CARsgen's BCMA-targeted CAR-T therapy zevor-cel has been included in China's inaugural Commercial Health Insurance Innovative Drug Catalogue for treating relapsed/refractory multiple myeloma. - Five-year clinical trial data showed 100% overall response rate with 78.6% achieving complete response, median progression-free survival of 44.1 months, and 76.9% survival at 60 months. - The inclusion in this new insurance catalogue aims to reduce patient financial burden and improve accessibility to advanced cell therapies across China.
- Jiangsu Vcare has entered an exclusive partnership with Huadong Medicine for commercialization rights of VC005 tablets in mainland China, with Vcare receiving RMB 50 million upfront and up to RMB 180 million in milestone payments. - VC005 is a second-generation, highly selective JAK1 inhibitor currently in Phase III trials for moderate-to-severe atopic dermatitis, with additional Phase III trials for ankylosing spondylitis and Phase II trials for vitiligo being initiated. - The partnership combines Vcare's innovative JAK1 inhibitor technology with Huadong Medicine's extensive commercial capabilities to address multiple autoimmune diseases in China's growing autoimmune therapeutics market. - VC005 demonstrates reduced JAK2 inhibition compared to JAK1, potentially mitigating safety concerns associated with excessive JAK2 inhibition while maintaining potent anti-inflammatory effects.
